ESCHERICHIA COLI O-POLYSACCHARIDE-PROTEIN CONJUGATE VACCINE

Abstract: The present invention relates to a method of producing an E. coli vaccine and to the vaccine produced thereby. The method involves purifying lipopolysaccharide from E. coli expressing complete O-polysaccharide sidechains; isolating the O-polysaccharide region of the lipopolysaccharide molecule by hydrolysis in dilute acetic acid and purifying it essentially free of lipid A; and covalently coupling lipid A-free O-polysaccharide via at least one hydroxyl or carboxyl group of the polysaccharide to a carrier protein. Polyvalent vaccines are prepared by combining two or more monovalent vaccines for different serotypes prepared according to the present invention. The present invention also relates to conjugates used in the vaccines. The conjugates of the present invention are the O-polysaccharide region of an E. coli lipopolysaccharide molecule covalently coupled to a carrier protein.

Description: "Escherichia coli O-Polysaccharide- Protein Conjugate Vaccine' BACKGROUND OF THE INVENTION Field of the Invention The present invention is directed to a method of producing a vaccine effective against one or more Escherichia coli (E. coli) strains. The present invention futher relates to a polyvalent vaccine composed of nonpyrogenic, nontoxic, immunogenic serotype-specific LPS based conjugates and to the conjugates therein. Description of the Art Escherichia coli (E. coli ) is the leading cause of life-threatening gram-negative bacterial sepsis. Both capsular (K) and lipopolysaccharide (LPS) (0) antigens are important virulence factors as described in Cross, A.S., Kim, K.S., Wright, D.C., Sadoff, J.C., Gemski, P. , "Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli , n J. Infect. Dis. 154: 497-503, 1986; and Pluschke, G. , Mayden, J., Achtman, M. , Levine, R.P., "Role of the capsule and 0 antigen in resistance of 018:K1 Escherichia coli to complement-mediated killing," Infect. Immun. 42: 907-913, 1983. Both capsular and LPS antigens can confer protection against the bactericidal effect of normal human serum, a characteristic which allows E. coli to invade and persist in the bloodstream as noted in Cross, A.S., ' Kim, K.S., Wright, D.C., Sadoff, J.c, Gemski, P., "Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli , " J. Infect. Dis. 154: 497-503, SUBSTITUTESHEET 1986; and Pluschke, G. , Mayden, J. , Achtman, M. , Levine, R.P., "Role of the capsule and O antigen in resistance of 018:K1 Escherichia coli to complement- mediated killing," Infect. Immun. 42: 907-913, 1983. Serospecific antibodies directed against either the capsular or LPS antigen can afford protection against experimental E. coli infections in animals as described by Cross, A.S., Zollinger, W. , Mandrell, R. , Gemski, P., Sadoff, J.C., "Evaluation of i munotherapeutic approaches for the potential treatment of infections caused by Kl- positive Escherichia coli , " J. Infect. Dis. 197: 68- 76, 1983; and Kaijser, B., Ahlstedt, S., "Protective capacity of antibodies against Escherichia coli O and K antigens," Infect. Immun. 17: 286-289, 1977. A limited number of both 0 and K antigens are expressed by E . coli strains which cause serious infections, such as septicemia, making vaccines composed of either antigen feasible as noted in ørskov, F, ørskov, I., "Escherichia coli extraintestinal infections," J. Hyg. 95: 551-575, 1985; Cross, A.S., Gemski, P., Sadoff, J.C., ørskov, F. , ørskov, I., "The importance of the Kl capsule in invasive infections caused by Escherichia coli , " J. Infect. Dis. 149: 184-193, 1984; and McCabe, W.R. , Kaijser, B. , Oiling, S., Uwaydah, M. , Hanson, L.A. , "Escherichia coli in bacteremia: K and 0 antigens and serum sensitivity of strains from adults and neonates," J. Infect. Dis. 138: 33-41, 1978. There are, however, two major drawbacks to the use of E. coli capsular antigens as human vaccines. First approximately 40% of E . coli bacteremic isolates cannot be serotyped as relates to capsular antigen. In addition, the Kl and K5 capsular antigens, which are expressed by more than SUBSTITUTESHEET 20% of K-typeable blood isolates, are poorly immunogenic in humans due to their antigenic cross- reactivity with mammalian glycosaminoglycans. Therefore, a K antigen-based E. coli vaccine would have a limited coverage, and hence, little utility. Based upon the above finding, a serospecific LPS-based vaccine would appear to possess the greatest potential to protect against E. coli extraintestinal infections. Native LPS, however, is far too toxic and pyrogenic for use as a human vaccine. The O serospecificity of E. coli is contained within the O-polysaccharide (O-PS) moiety of the LPS molecule as for other gram-negative bacteria. The O-PS region can be separated from the toxic lipid A portion of the LPS molecule by cleavage in dilute acetic acid followed by pelleting of the insoluble lipid A moiety by centrifugation. While O-PS isolated in this manner is serologically reactive nontoxic and non pyrogenic, it is non- immunogenic due to its small molecular weight as noted in Pier, G.B. , Sidberry, H.F., Sadoff, J.C., "Protective immunity induced in mice by immunization with high molecular polysaccharide from Pseudomonas aeruginosa , " Infect. Immun. 22: 919-925, 1978; and Chester, I.R., Meadow, P.M., Pitt, T.L., "The relationship between O-antigenic lipopolysaccharides and serological specificity in strains of Pseudomonas aeruginosa of different O-serotypes," J. General Microbiol. 78: 305-318, 1973. One means by which to produce a protective immune response to isolated O-PS is to covalently couple it to a carrier protein, yielding a conjugate vaccine. Escherichia coli 018 O-PS has been covalently coupled to both cholera toxin and Pseudomonas aeruginosa toxin A, yielding safe, SUBSTITUTESHEET immunogenic, and protective monovalent conjugate vaccines as described in Cryz, S.J., Jr., Cross, A.S., Sadoff, J.C., Fϋrer, E. , "Synthesis and characterization of Escherichia coli 018 0- polysaccharide conjugate vaccines," Infect. Immun. 58: 373-377, 1990; and Cryz, S.J., Jr., Cross, A.S., Sadoff, J.C., Wegmann, A., Que, J.U. , Fϋrer, E. , "Safety and immunogenicity of Escherichia coli 018 O-specific polysaccharide (O-PS)-toxin A and O-PS- cholera toxin conjugate vaccines in humans," J. Infect. Dis. 163: 1040-1045, 1991. However, any vaccine against E. coli based on serospecific O-PS determinants would have to be multi-valent based upon the observation that the majority (-70%) of bacteremic infections are caused by 10-12 different serotypes of E. coli . Serospecificity is conferred by both the monosaccharide composition of O-PS and the type of chemical linkage between each monosaccharide as noted in ørskov, F., ørskov, I., "Serotyping of Escherichia coli , " Methods in Microbiology 14: 43- 112, 1984. Therefore, the conditions used to synthesize the above described 018 monovalent conjugate might not be suitable for other serotypes of E. coli . By the present invention, isolated O-PS from 12 serotypes of E. coli were covalently coupled to P . aeruginosa toxin A which serves as a "carrier protein" for the O-PS. The conditions employed to covalently couple toxin A to _. coli O-PS effectively detoxify the toxin A molecule and preserve the antigenicity of the O-PS moiety. The resulting polyvalent conjugate was found to be safe and immunogenic in humans when administered by the parenteral route. SUBSTITUTE SHEET SUMMARY OF THE INVENTION Accordingly, it is an object of the present invention to provide a means of producing a polyvalent nontoxic vaccine against E. coli which is effective against the different E. coli serotypes. It is another object of the present invention to provide monovalent O-PS-toxin A conjugates specific for various E. coli serotypes for use in a polyvalent vaccine. In one embodiment, the present invention describes a method of producing a polyvalent nontoxic, immunogenic E. coli O-PS-toxin A conjugate vaccine. The method includes deriving O-PS from specific strains of E. coli shown to produce good levels of smooth LPS possessing complete O-PS regions; oxidizing the O-PS under strictly controlled conditions to produce reactive aldehyde groups; covalently introducing a spacer molecule into toxin A by the use of a water-soluble carbodiimide as a coupling agent; and contacting the toxin A-spacer molecule with oxidized polysaccharide to form monovalent nontoxic, immunogenic O-PS-toxin A conjugate vaccine. In another embodiment, the present invention relates to a nontoxic, immunogenic E. coli vaccine formulated by combining monovalent O-PS- toxin A conjugate vaccines of differing serotypes to form a polyvalent vaccine. In a further embodiment, the present invention relates to a conjugate comprising the O- polysaccharide region of an E. coli lipoplysaccharide molecule covalently coupled to a carrier protein. SUBSTITUTESHEET Various other objects and advantages of the present invention will become apparent from the following description of the invention. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to E. coli- protein conjugates for use in vaccines against E. coli . The present invention further relates to a method of producing such vaccines. The novel method of the present invention produces a polyvalent nontoxic, immunogenic vaccine against E. coli . Utilizing the method of the present invention, monovalent serotype-specific conjugates are prepared and combined to yield a polyvalent vaccine. The immunogenic vaccine comprises conjugates of the present invention in an amount sufficient to elicit a humoral antibody response and a pharmaceutically acceptable carrier. In the method of the present invention, the vaccine conjugates are prepared by isolating 0- PS from E. coli strains which produce good levels of smooth LPS possessing complete O-PS regions. Suitable E . coli strains based upon seroepidemiological surveys include, but are not limited to, serotypes 01, 02, 04, 06, 07, 08, 012, 015, 016, 018, 025 and 075. The O-PS is isolated so as to be essentially free of lipid A and oxidized to produce reactive aldehyde groups. Preferably, 40 to 80% of the available reducing sugars of the O-PS are oxidized during the treatment. For example, the 0- PS can be oxidized by exposure to NaI0 4 , preferably for less than 5 minutes, more preferably for 2-5 minutes. SUBSTITUTE SHEET The conjugate is then formed by covalently coupling lipid A-free O-polysaccharide through at least one hydroxyl or carboxyl group to a carrier protein. Suitable carrier proteins for use in the present invention include, for example, toxin A, tetanus toxoid, cholera toxin, diphtheria toxoid, protein CRM 197 produced by Corynebacterium diphtheriae , outer membrane proteins from gram- negative bacteria, specifically group B Neiεseria meningitidis, heat labile toxin of Escherichia coli , the B subunit from either cholera toxin or heat labile toxin of E . coli or bacterial heat-shock proteins. The carrier protein can be coupled directly to the O-PS or via a spacer molecule. A prefered carrier protein is toxin A which is coupled to the purified O-PS by a spacer molecule, such as, adipic acid dihydrazide. The spacer molecule irreversibly detoxifies toxin A and as well as functioning as a bifunctional spacer molecule which can be bound to O-PS. Polyvalent vaccines are produced by combining two or more monovalent conjugates prepared from O-PS of different serotypes as described above. For example, a polyvalent vaccine of the present invention can contain conjugates composed of O-PS from serotypes 02, 04, 06 and 018, or 02, 04, 06, 07, and 018, or 01, 02, 04, 06, 07, 08 and 018, or 01, 02, 04, 06, 07, 08, 012 and 018, or 01, 02, 04, 06, 07, 08, 012, 015 and 018, or 01, 02, 04, 06, 08, 012, 015, 016 or 018, or 01, 02, 04, 06, 07, 08, 012, 015, 016, 018 and 025, or 01, 02, 04, 06, 07, 08, 012, 015, 016, 018, 025 and 075. Conjugates of the present invention, formed as described above, have a molecular weight of greater than 600,000. Unlike native LPS and SUBSTITUTESHEET toxin A, conjugates to the present invention are nontoxic. Moreover, unlike native LPS, the conjugates are nonpyrogenic. The conjugates of the present invention are immunogenic engendering an antibody response to both the O-PS and toxin A moieties. The following non-limiting examples are provided to further illustrate the present invention. In generating the data included herein, the E. coli strains listed below in Table 3 were used as the source of LPS. It is to be understood, however, that other strains of E. coli expressing the same serotypes may be used contingent upon their synthesizing a smooth LPS structure containing complete O-PS, though not necessarily with equivalent results. Preparation of O-PS-Toxin A Conjugates Nontoxic, immunogenic conjugates of the present invention were synthesized by covalently linking O-PS containing serospecific determinants derived from hydrolyzed E. coli LPS to toxin A. Adipic acid dihydrazide (ADH) was used as a spacer molecule. The covalent linking of ADH to toxin A results in the complete destruction of the adenosine diphosphate ribose-transferase activity which renders toxin A nontoxic as described in Cryz, S.J. , Jr., Fύrer, E. , Sadoff, J.C., Germanier, R. , "Pseudomonas aeruginosa immunotype 5 polysaccharide- toxin A conjugate vaccine," Infect. Immun. 52: 161- 165, 1986. Conjugates synthesized in this manner from O-PS derived from LPS of the 12 most common serotypes of E. coli associated with sepsis possessed a molecular weight of greater than SUBSTITUTE SHEET 600,000, were nontoxic, nonpyrogenic, and immunogenic. Antibody engendered by this vaccine in both rabbits and humans was protective against experimental E. coli infections when passively transferred to mice. Vaccination elicited both an anti-ϋ". coli LPS and an antitoxin A IgG antibody response. By the method of the present invention, LPS was isolated and purified as described by Cryz, S.J., Jr, Cross, A.S., Sadoff, J.C., Fiirer, E. , "Synthesis and characterization of Escherichia coli 018 O-polysaccharide conjugate vaccines," Infect. Immun. 58: 373-377, 1990. LPS prepared in this manner contained less than 2% (wt/wt) protein and nucleic acids. O-PS containing serospecific antigenic determinants was derived from purified LPS by mild acid hydrolysis. Purified LPS (1 g) was suspended in 200 ml of a 1% (vol/vol) acetic acid in water solution. The solution was placed in a round bottle fitted with a reflux-cooler and boiled for 90 minutes in a hemispherical flask heater. After cooling, the insoluble lipid A was pelleted by centrifugation and discarded. The supernatant was neutralized with 0.2 N NaOH and filter-sterilized through a 45 μm filter to remove traces of lipid A. The solution was concentrated by rotary evaporation under reduced pressure. The concentrate was passed through a 5 x 40 cm G-25 column (Pharmacia Fine Chemicals, Uppsala, Sweden) equilibrated in distilled water. The fractions were collected and analyzed for carbohydrate content using the phenol- sulfuric acid method as described by Westphal, 0., Luderitz, 0., Bister, F. , "Ueber die Extraction von Bakterien it Phenol-Wasser," Z. Naturforsch [B] 7: 148-155, 1952. The carbohydrate containing SUBSTITUTESHEET fractions (M r <70,000) were pooled, concentrated by rotary evaporation, sterilized through passage through a 0.22 μm filter, and lyophilized. The lyophilized material was analyzed for pyrogenicity in rabbits at an intravenous dose of 10 μg per kilogram body weight. Only pyrogen-free material was used to prepare the conjugates. Toxin A was purified as described in Cryz, S.J., Jr, Fύrer, E. , Germanier, R. , "Protection against P. aerugrinosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase and antilipopolysaccharide," Infect. Immun. 39: 1072-1079, 1983, except that the production strain was a spontaneously isolated hyperproducer of toxin A derived from P. aeruginosa strain PA103, termed PA103-FeR. The final purified preparations consisted of greater than 95% toxin A protein as determined by high pressure liquid chromatography. The O-PS was next oxidized to generate reactive aldehyde groups as follows. Lyophilized O- PS (60 mg) was reconstituted in 12 ml of distilled water. Solid NalO * . (258 mg; E. Merck and Co., Darmstadt, Germany) was added and the reaction allowed to proceed for 2 minutes. The oxidation reaction was stopped by the addition of ethylene glycol (0.12 ml). The length of time that the O-PS was exposed to NalO.-, during the oxidation process was found to be critical as concerns the immunogenicity of the oxidized O-PS upon coupling to toxin A. Conjugates constructed of O-PS oxidized for more than 5 minutes were found to be reduced in immunogenicity as shown below in Table l. This trend was consistent for all 3 serotypes of O-PS studied and appeared to be related to the extent to SUBSTITUTE SHEET which the O-PS was oxidized. This finding indicates that critical epitopes expressed by E__ coli O-PS are readily destroyed by excessive oxidation. This was an unexpected finding over Cryz, S.J., Fύrer, E.P., "Nontoxic Pseudomonas aeruginosa polysaccharide- tetanus toxoid and polysaccharide-toxin A conjugate vaccines," United States Patent 4,771,127, 10/88, where it was shown that the O-PS from P. aeruginosa could be oxidized in the presence of NalO* for 2 hours and still yield a highly immunogenic conjugate when coupled to a suitable carrier protein. Table l shows the effect of different oxidation times on the immunogenicity of O-PS conjugate vaccines. SUBSTITUTESHEET TABLE 1 Effect of the Extent of Oxidation Time on the Immunogenicity of O-PS Conjugates Immunogenicity 1 [Mean IgG ELISA Titer (range) ] 71 (18-244) 44 (18-201) 23 (18-33) 67 (51-90) CO 8.3 (0-48) C 03 CO 61 (32-100) H C 10 (6-24) m 0 CO _c Rabbits (3 per group) were immunized on days 0 and 14 with an amount of conjugate equal m ttoo 5500 μμgg ooff OO--PS. m ND = not done, The mixture was concentrated by rotary evaporation under reduced pressure and the oxidized O-PS was separated from other reactants by filtration over Sephadex G-25 (Pharmacia Fine Chemicals, Uppsala, Sweden) . Column fractions were collected and monitored for carbohydrate content by the phenol-sulfuric acid method described in Dubois, M., Gilles, K.A. , Hamilton, J.K. , Rebers, P.A. , Smith, F. , "Colorimetric method for determination of sugars and related substances," Anal. Chem. 28: 350-356, 1956. The fractions containing oxidized O-PS were pooled and lyophilized. Adipic acid dihydrazide (ADH) was utilized for two purposes: (i) to irreversibly detoxify toxin A following its covalent coupling to the toxin A molecule; and (ii) to act as a spacer molecule by virtue of its 2 reactive groups, one of which is bound to toxin A, the other of which is available to combine with OPS. ADH was covalently coupled to toxin A as follows. Solid ADH (300 mg; Fluka AG, Buchs, Switzerland) and l-ethyl-3(-3-dimethy1- a inopropyl) carbodiimide (30 mg; Sigma Chemical Co., St. Louis, MO) were added to 150 mg of toxin A (5 mg/ml in 0.05 M Na 2 HPO-NaH 2 PO , pH 7.2). The solution was stirred for 2 hours at 22°C during which time the pH of the solution was maintained at 4.8 by the addition of 0.3 N HC1 using a pH-stat (Methrom, Herisan, Switzerland) . The toxin A-ADH solution was then extensively dialyzed against 0.05 M phosphate buffered saline, pH 7.2 (PBS) . The solution was centrifuged at 5,000 x g for 10 minutes to remove any insoluble material. Toxin A-ADH was coupled to oxidized O-PS as follows. The toxin A-ADH solution was diluted in 50 mM phosphate buffer, pH 7.0, at a final SUBSTITUTESHEET concentration of 2 mg/ml. An equal amount of oxidized O-PS was added and the mixture incubated for 1 hour at 22°C. NaCNBH 3 was added to a final concentration of 20 mM and the solution incubated an additional 72-96 hours at 22°C. This mixture was extensively dialyzed against PBS containing 0.02% Merthiolate (PBS-M) and applied to a Sephadex G-100 column equilibrated in PBS-M. The column was eluted with PBS-M and the conjugate-containing void volume fractions collected and stored at 4°C. The final polyvalent vaccine was produced as follows. The 12 monovalent conjugates were combined and mixed under aseptic conditions in such a manner that the final solution contained 50 μg of each polysaccharide serotype per ml (equal to 600 μg/ml) . This mixture was then dialyzed against 10 volumes of half-strength PBS containing 5% (wt/vol) lactose and 0.01% Merthiolate. The mixture was aseptically withdrawn from the dialysis bag, and 1 ml was placed into 3-ml sterile glass vials. The vials were capped, and lyophilized under aseptic conditions. The caps were fitted in situ , sealed with aluminum caps, and the vials labeled. Characteristics of O-PS-Toxin A Conjugate Vaccine Various physicochemical, safety, and immunogenic characteristics of the O-PS-toxin A conjugate vaccines are shown in Tables 1-8. In specific regard to Table 1, the immunogenicity of the conjugates were found to be dependent upon the time over which the O-PS was exposed to NalO, as part of the oxidation step to generate reactive aldehyde groups, essential for subsequent conjugate formation. The length of exposure to NalO,, affects the degree to which the O-PS is oxidized. For three SUBSTITUTESHEET different serotypes of O-PS, it was shown that exposure to NalO. longer than 5 minutes at ambient temperature, which results in >80% of sugars residues being oxidized, resulted in poorly immunogenic conjugates upon coupling to a carrier protein. Conjugates formulated with O-PS oxidized for 2 to 5 minutes yielded conjugates which were more immunogenic. Various characteristics (molecular weight, toxicity, pyrogenicity, and immunogenicity) of LPS, O-PS, toxin A, and O-PS-toxin A conjugates are shown below in Table 2. The conjugates possessed a molecular weight greater than 600,000, which exceeded the molecular weight of their respective starting constituents, i.e. O-PS (<70,000) and toxin A (-66,000). LPS and toxin A were toxic for mice in their native forms. For example, the mean lethal dose for native toxin A when injected intraperitoneally was 0.2 μg/mouse. However, the covalent coupling of toxin A to O-PS resulted in a marked reduction in toxicity evidenced by the fact that there was no indication of toxicity when mice received the equivalent of 200 μg of toxin A protein as conjugate. Therefore, the methods used to construct the conjugate vaccines resulted in at least a 1,000-fold reduction in the toxicity of toxin A, in effect yielding a toxin A toxoid. Native LPS was pyrogenic when administered intravenously at a dose of 0.1 μg/kg rabbit body weight. In contrast, both the purified O-PS and O- PS-toxin A conjugates were nonpyrogenic when administered at a dose of >10 μg/kg. Due to its highly toxic nature, native toxin A was not assayed for pyrogenicity. Unconjugated O-PS was non- immunogenic when injected intramuscularly into SUBSTITUTESHEET rabbits. In contrast, all 12 monovalent O-PS-toxin A conjugate vaccines as well as the 12-valent conjugate vaccine were able to induce an immune response to each O-PS serotype and to toxin A. SUBSTITUTE SHEET TABLE 2 C CD in C Determined by high pressure liquid chromatography using a Dupont Zorbax GF-250 tn column. Expressed as mean lethal dose following intraperitoneal injection into 18-20 g mice. For LPS experiments, mice were first sensitized with glactoseamine. Nontoxic signifies that a minimum 500 μg of antigen administered intraperitoneally resulted in no mortality. The dose of antigen, expressed in μg/kg body weight, which when injected into rabbits by the intravenous route, resulted in a >0.3°C increase in body temperature. ND = not done. Determined by immunizing groups of rabbits with 10 to 50 μg of each antigen. Sera were analyzed for the presence of specific IgG antibody by ELISA. In summary, the data presented in Table 1 shows that the O-PS-toxin A conjugate vaccines were of a high molecular weight, nontoxic, nonpyrogenic, and able to induce a specific antibody response to both the O-PS and toxin A conjugate components. The strains which provided the LPS from which the O-PS were isolated are shown in Table 3. These 12 serotypes were selected based upon seroepidemiological studies showing E . coli expressing these serotypes to be frequently associated with bacteremic episodes. These particular strains were selected based upon their ability to produce a substantial amount of smooth LPS possessing complete O-PS sidechains as determined by analysis of the LPS by sodium dodecylsulfate polyacrylamide gel electrophoresis followed by silver staining to visualize the bands. Other strains expressing these characteristics may be used although not necessarily with the same results. SUBSTITUTE SHEET TABLE 3 E. coli Strains Used for Isolation of LPS & O-PS Strain designation Serotype Source 204 01 A. Brauner Karolinska Hospital Stockholm, Sweden 171 02 A. Brauner Karolinska Hospital Stockholm, Sweden 47 04 Walter Reed Army Institute SUBSTITUTE SHEET The composition of the 12 monovalent O-PS- toxin A conjugate vaccines (that is the ratio of O-PS and toxin A) prepared from O-PS of differing serotypes is shown below in Table 4. These monovalent conjugates were combined to form the polyvalent vaccine. The conjugates were composed of between 33.4% to 54.7% O-PS and 46.3% to 66.6% toxin A. Therefore, while the relative ratio of O-PS to toxin A may vary from serotype to serotype, it is preferable that each conjugate contains a minium of 30% O-PS by weight. SUBSTITUTESHEET The ability of the polyvalent conjugate vaccine to elicit an i munoglobin G (IgG) antibody response in rabbits to each of the 12 LPS serotypes and to toxin A is shown below in Table 5. Immunization engendered at a 4-fold rise in mean IgG ELISA titer to all 13 vaccine antigens (12 LPS serotypes plus toxin A) . TABLE 5 Rabbits (3) were immunized on days 0 and 14 with an amount of vaccine equal to 25 μg O-PS from each of the 12 serotypes. SUBSTITUTE SHEET The ability of passively transferred IgG antibody isolated from the serum of rabbits immunized with the polyvalent O-PS-toxin A vaccine to protect mice against fatal experimental E. coli sepsis caused by infection with the 12 serotypes of E. coli is shownin Table 6. Passively administered IgG, which contained elevated antibody titers to all 8 serotypes expressed by the challenge strains, significantly decreased the mortality rate when compared to the control groups, which received only buffer. TABLE 6 Approximately 3 mg of IgG purified from the sera of rabbits immunized with the 12-valent E. coli O-PS-toxin A conjugate vaccine were administered intrapritoneally (IP) to mice about 3 to 5 hours prior to IP challenge with E. coli. SUBSTITUTE SHEET Safety and Immunogenicity of the Polyvalent O-PS-Toxin A Vaccine in Humans A polyvalent vaccine was prepared by combining 12 sterile monovalent conjugates composed of O-PS isolated from strains listed in Table 3 coupled to toxin A. Tests for sterility, pyrogenicity, and general safety were performed according to the procedures detailed in the United States Code of Federal Regulations 21.610. The polyvalent conjugate vaccine used for this example was composed of 43% O-PS and 57% toxin A. It was nonpyrogenic when administered intravenously to rabbits at a dose of 12 μg/kg body weight. There were no mortalities nor any sign of overt toxicity when 0.5 ml and 5.0 ml of reconstituted vaccine were administered intraperitoneally to mice and guinea pigs, respectively. The vaccine was stable to toxic reversion. Therefore, the intraperitoneal administration of 100 μg of toxin A protein as conjugate per mouse, which had previously been reconstituted and stored at 37°C for 28 days, caused no overt signs of toxicity. Healthy adult volunteers received a total of 698 μg of conjugate (equal to 300 μg of total O- PS [25 μg O-PS/serotype] and 398 μg of toxin A) in 0.5 ml administered intramuscularly in the deltoid area. All reactions subsequent to vaccination were recorded by the volunteer on a control sheet. Venous blood samples were drawn just prior to vaccination and at 28 days post-vaccination. The sera were collected as described in Cryz, S.J., Jr., Cross, A.S., Sadoff, J.C., Wegmann, A., Que, J.U. , Fϋrer, E. , "Safety and immunogenicity of Escherichia coli 018 o-specific polysaccharide (O-PS)-toxin A SUBSTITUTE SHEET and O-PS-cholera toxin conjugate vaccines in humans," J. Infect. Dis. 163: 1040-1045, 1991. Reactions to vaccination are detailed below in Table 7. Most (85%) of the vaccinees noted mild pain at the injection site while swelling and redness were reported by 30% and 20% of subjects, respectively. Only 3 subjects reported a systemic reaction, which consisted of headache (1) and malaise (2) . No reactions hindered normal activities and all resolved spontaneously within 24- 72 hours. SUBSTITUTESHEET TABLE 7 Reactions Following Vaccination With E. coli O-PS-Toxin A Polyvalent Vaccine Local Reactions (%) Systemic Reactions (%) in s Pain Swelling Redness Fever Chills Malaise Headache I ) H 85 30 20 0 0 Ϊ0 5 m Twenty healthy adult volunteers received a single dose of the vaccine containing 25 X μg O-PS per vaccine serotype intramuscularly. Immunization with the polyvalent O-PS- toxin A conjugate vaccine resulted in a substantial rise in mean anti-LPS IgG values to 11 of the 12 serotypes, the exception being serotype 016 (1.4- fold rise)as shown below in Table 8. The mean-fold rises ranged from 2.8-fold (012) to 20-fold (06). It is important to note that a far more vigorous response was noted in subjects whose baseline anti- LPS IgG levels were <10 μg/ml. This type of "epitopic suppression" by high levels (>10 μg/ml) of specific preexisting antibodies has been widely reported in the literature. SUBSTITUTESHEET TABLE 8 IΛ c in X Volunteers received a single dose containing 25 μg of O-PS from each of the 12 vaccine serotypes on day 0. While a preferred embodiment of the invention have been described herein, it will be obvious to those skilled in the art that various changes and modifications, especially pertaining to vaccine formulation as related to the number of serotypes of O-PS incorporated, may be made without departing from the spirit of the invention as defined in the following claims. All publications given hereinabove are hereby incorporated by reference. SUBSTITUTESHEET

Claims: WHAT IS CLAIMED IS: 1. A method of producing an E. coli vaccine comprising the steps of: purifying lipopolysaccharide from E. coli expressing complete O-polysaccharide sidechains; isolating the O-polysaccharide region of the lipopolysaccharide molecule by hydrolysis in dilute acetic acid and purifying it essentially free of lipid A; and covalently coupling lipid A-free O- polysaccharide via at least one hydroxyl or carboxyl group of said polysaccharide to a carrier protein. 2. A conjugate comprising the O- polysaccharide region of an E. coli lipoplysaccharide molecule covalently coupled to a carrier protein. 3. The conjugate according to claim 2 wherein said conjugate has a molecular weight greater than 600,000. 4. The conjugate according to claim 2 further comprising a bifunctional spacer molecule wherein said O-polysaccharide is covalently linked to said carrier protein through said spacer molecule. 5. The conjugate according to claim 4 wherein said spacer molecule is adipic acid dihydrazide. 6. The conjugate according to claim 2 wherein said carrier protein is selected from the SUBSTITUTE SHEET following: toxin A, tetanus toxoid, cholera toxin, diphtheria toxoid, protein CRM 197 produced by Corynebacterium diphtheriae , outer membrane proteins from gram-negative bacteria, specifically group B Neisseria meningitidis , heat labile toxin of Escherichia coli , the B subunit from either cholera toxin heat labile toxin of E. coli , or bacterial heat shock proteins. 7. The method according to claim 1 wherein said purified O-PS component is exposed to an oxidizing agent for a period of time sufficient to oxidize 40% to 80% of available reducing sugars. 8. The method according to claim 7 wherein the oxidzing agent is NalO.. 9. An £. coli nontoxic, nonpyrogenic, immunogenic vaccine comprising said conjugate according to claim 2 and a pharmaceutically- acceptable carrier wherein said conjugate is present in an amount sufficient to elicit a humoral antibody response. 10. A method of preparing a polyvalent E. coli vaccine comprising the steps of: preparing two or more monovalent vaccines according to the method of claim 1 from different O- polysaccharide serotypes; and combining at least two different serotypes of monovalent vaccines. 11. The method of claim 10 wherein said monovalent vaccines are composed of serotypes 02, 04, 06, and 018 polysaccharides. SUBSTITUTESHEET 12. The method of claim 10 wherein said monovalent vaccines are composed of serotypes 02, 04, 06, 07, and 018 polysaccharides. 13. The method of claim 10 wherein said monovalent vaccines are composed of serotypes 01, 02, 04, 06, 07, 08, and 018 polysaccharides. 14. The method of claim 10 wherein said monovalent vaccines are composed of serotypes 01, 02, 04, 06, 07, 08, 012, and 018 polysaccharides. 15. The method of claim 10 wherein said monovalent vaccines are composed of serotypes 01, 02, 04, 06, 07, 08, 012, 015, and 018 polysaccharides. 16. The method of claim 10 wherein said monovalent vaccines are composed of serotypes 01, 02, 04, 06, 07, 08, 012, 015, 016, and 018 polysaccharides. 17. The method of claim 10 wherein said monovalent vaccines are composed of serotypes 01, 02, 04, 06, 07, 08, 012, 015, 016, 018, and 025 polysaccharides. 18. The method of claim 10 wherein said monovalent vaccines are composed of serotypes 01, 02, 04, 06, 07, 08, 012, 015, 016, 018, 025, 075 polysaccharides. SUBSTITUTE SHEET

Inventors: CRYZ STANLEY J, FURER EMIL P, CRYZ, STANLEY, J., FURER, EMIL, P.
Applicants: CRYZ STANLEY J, CRYZ, STANLEY, J.
Application year: 1992
Main classification: A61K39
IPC codes: A61K39, A61K47, A61P31